Global
Germany
You are now leaving the global website of Oncopeptides AB, Sweden. The link you clicked will take you the website of our German operations at oncopeptides.de
Spain
You are now leaving the global website of Oncopeptides AB, Sweden. The link you clicked will take you the website of our Spanish operations at oncopeptides.es
Austria
Italy
You are now leaving the global website of Oncopeptides AB, Sweden. The link you clicked will take you the website of our Italian operations at oncopeptides.it
Change Language
Global
Germany
You are now leaving the global website of Oncopeptides AB, Sweden. The link you clicked will take you the website of our German operations at oncopeptides.de
Spain
You are now leaving the global website of Oncopeptides AB, Sweden. The link you clicked will take you the website of our Spanish operations at oncopeptides.es
Austria
Italy
You are now leaving the global website of Oncopeptides AB, Sweden. The link you clicked will take you the website of our Italian operations at oncopeptides.it
Change Language
Sofia Heigis, CEO of Oncopeptides, recently visited the Biostock studio to present the company, its’ ambitions for Pepaxti in Europe and rest of the world and also outline the company´s strategic pivot into a multi-indication global biotech, spearheaded by its glioblastoma project.
The presentation is followed by a Q&A session with Jonas Söderström, managing partner at Biostock.
You can also watch a longer interview with Sofia here.